• Amikacin Sulfate: From Ribosome to Granuloma

  2026-09-22

  Amikacin Sulfate offers a useful translational model for connecting ribosomal bactericidal activity with intracellular and granuloma-focused exposure. This article examines how researchers can move beyond simple potency claims by integrating assay context, functional selection logic, targeted delivery, and therapeutic-index strategy.

• APEX2, TERT Expression, and DNA Repair in Stem Cells

  2026-09-22

  This reference study identifies APEX2 as a DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells and melanoma cells, distinguishing it from APEX1. Its RNA-seq and chromatin-binding results connect TERT regulation to repetitive DNA elements, especially MIR sequences, suggesting that local DNA repair may support transcription.

• Topotecan: From DNA Lesions to Assay Decisions

  2026-09-21

  Topotecan and its synonym SKF104864 connect topoisomerase I–DNA damage to clinically relevant cancer models. This evidence-calibrated guide explains how to select endpoints, interpret concentration data, and bridge glioma and pediatric studies with ovarian cancer evidence.

• 7-Ethyl-10-hydroxycamptothecin: Mechanism-First Assays

  2026-09-21

  7-Ethyl-10-hydroxycamptothecin, also known as SN-38, is more than a cytotoxic control: it can anchor mechanism-first studies of topoisomerase I inhibition, cell-cycle disruption, and apoptosis. This guide shows how to separate established evidence from assay interpretation in advanced colon cancer research.

• Genotyping Kit for target alleles: Fast PCR Workflow

  2026-09-20

  Accelerate allele screening across insects, tissues, fishes, and cells with a single-tube DNA preparation workflow and dye-containing PCR master mix. This practical guide connects rapid genotyping with mechanistic studies such as the E-cadherin-focused colitis research reported in PLOS Pathogens.

• Carfilzomib (PR-171) Research Workflows

  2026-09-19

  Carfilzomib (PR-171) enables tightly controlled studies of irreversible proteasome inhibition, proteotoxic stress, and cancer-cell death. This practical guide connects dose–response, pulse-exposure, combination, and biomarker workflows with troubleshooting strategies for reproducible translational research.

• Cepharanthine: From Apoptosis to Translation

  2026-09-18

  A translational framework for positioning Cepharanthine across apoptosis research, patient-derived organoids, endometriosis models, oncology combinations, and chemotherapy side effect mitigation.

• EGCG Nanoparticles Strengthen FLASH-RT

  2026-09-18

  Xu et al. developed functionalized self-assembled EGCG nanoparticles, termed BENPs, to increase ROS generation and tumor-cell DNA damage during FLASH radiotherapy while also promoting antitumor immune responses. The study provides a preclinical framework for combining radiosensitization, tumor control, and immune profiling without assuming that increased radiation dose alone will improve FLASH-RT efficacy.

• Mubritinib–HSA Binding: Methods and Key Findings

  2026-09-17

  This study characterizes how the mitochondrial electron transport chain inhibitor mubritinib interacts with human serum albumin using fluorescence, biochemical, and molecular docking approaches. Its findings connect moderate site I binding with local structural changes and inhibition of albumin esterase-like activity, providing a useful framework for interpreting transport, distribution, and pharmacologic behavior.

• MEK Inhibition, Radiotherapy, and T-Cell Function

  2026-09-17

  This study identifies a mechanistic link between MEK inhibition, radiotherapy-induced DNA damage, cGAS–STING signaling, and CXCL10-dependent T-cell recruitment in KRAS-mutant lung cancer. Its results support combining MEK inhibition with carefully selected radiation schedules to improve immune activation while highlighting the need for mechanistic validation in additional models.

• Topotecan Workflows for Cancer Research

  2026-09-16

  Topotecan, also known as SKF104864, is a practical topoisomerase I stressor for connecting DNA damage, cell-cycle behavior, and apoptosis across cancer models. This guide translates its ovarian-cancer evidence base into reproducible in vitro, glioma, and pediatric tumor workflows with formulation and interpretation safeguards.

• Forsythoside E: PKM2 Workflow for Sepsis Studies

  2026-09-16

  Forsythoside E is a mechanistically differentiated pyruvate kinase M2 (PKM2) inhibitor for linking macrophage metabolism with inflammatory signaling. This guide converts its PKM2 tetramerization, STAT3 phosphorylation suppression, and in vivo liver-protection profile into practical cell, biophysical, and mouse-study workflows.

• HyperFusion™ Polymerase for C. elegans Assays

  2026-09-15

  Discover how HyperFusion high-fidelity DNA polymerase can strengthen PCR evidence chains in C. elegans neurodegeneration research. This article translates pheromone-signaling biology into assay design, controls, and sequencing-ready workflows rather than simply describing enzyme performance.

• Plerixafor (AMD3100): From Target to Phenotype

  2026-09-15

  Plerixafor (AMD3100) is more than a CXCR4 pathway blocker: it is a mechanistic reference for separating receptor engagement from migration, tumor biology, and cell-trafficking phenotypes. This guide interprets the latest colorectal cancer evidence and translates it into better assay-selection decisions.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-09-14

  The reference study develops a patient-specific gastric cancer assembloid by combining matched tumor organoids with tumor-derived stromal subpopulations. Its findings show that stromal context alters gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor biology, resistance mechanisms, and personalized treatment responses.

8570 records 5/572 page Previous Next 12345 下5页 Last page